Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
IPO-day purchase at offering price ($16.00). Bihua Chen (Cormorant Asset Management) previously held pre-IPO preferred stock (Series A & B); the 312,500 P-coded shares represent fresh capital added at the listing. BLSM raised $150M upsized IPO on Nasdaq for EGFR-mutant lung cancer inhibitor BH-30643. Now $15.99 (−0.1% from buy).
IPO-day purchase at offering price ($18.00). Foresite Capital held ~15% post-IPO stake from pre-IPO preferred; this adds 140,000 shares of common at the offering close. Latigo raised $345.6M for non-opioid pain pipeline (Nav1.8 inhibitor). Now $18.56 (+3.1% from buy).
Open-market accumulation in 13 tranches across August 6–10, 2026 at $15.64–$16.72 (weighted avg ~$16.40). Aug 10 tranches alone total ~$647K. Prescott Group is an existing 10%+ activist holder adding on price weakness. Now $15.77 (−3.8% from avg buy price).
AIThe day in insider buying
SEC Form 4 Insider Scan — August 11, 2026
Scanned the last 24 hours of EDGAR Form 4 filings (filed August 10–11, 2026). 3 qualifying buys (≥ $250K, transaction type P) totalling $9.84M. The dominant theme is a pair of biotech IPO closings — BlossomHill Therapeutics (BLSM) and Latigo Biotherapeutics (LTGO) both priced and closed their offerings on August 10, drawing combined insider commitments of $7.52M at the offering price. The third buy is an ongoing open-market accumulation in Nature's Sunshine Products (NATR) by activist large shareholder Prescott Group.
Headline Filings
BLSM — Bihua Chen (Director, Cormorant Asset Management) bought 312,500 shares ≈ $5.00M at $16.00 avg; now $15.99 (−0.1% since buy). IPO-day purchase on August 10. BLSM raised $150M in its upsized Nasdaq IPO targeting EGFR-mutant lung cancer (EGFR C797S inhibitor BH-30643). Cormorant participated in Series A & B and added fresh capital at the offering price. (filing)
LTGO — James B. Tananbaum / Foresite Capital Management V (Director, 10% Owner) bought 140,000 shares ≈ $2.52M at $18.00 avg; now $18.56 (+3.1% since buy). Foresite was already LTGO's second-largest pre-IPO investor (~15% post-IPO stake); the $2.52M purchase represents incremental conviction at the offering price. Latigo raised $345.6M in its upsized IPO for a non-opioid pain pipeline (Nav1.8 inhibitor). (filing)
NATR — Phil Frohlich / Prescott Group Capital Management (10% Owner) accumulated 141,389 shares ≈ $2.32M at $15.64–$16.72 (weighted avg ≈ $16.40) over August 6–10, 2026 (Form 4 filed August 10); now $15.77 (−3.8% from avg buy). August 10 tranches alone total ~$647K. Ongoing open-market accumulation by an existing activist 10%+ holder. Nature's Sunshine is a legacy direct-sales nutrition company; Prescott Group holds a large position and appears to be adding aggressively on weakness. (filing)
Notes
Theme: Biotech IPO conviction buys. BLSM and LTGO dominate the dollar value; both are newly public biotech names where pre-IPO sponsors purchased additional shares at the offering price — a modestly bullish signal since it commits fresh cash at a price with a public lockup. LTGO is now in the green (+3.1%); BLSM is effectively flat at IPO. Both are small-cap clinical-stage names with meaningful binary risk.
NATR stands apart as the only genuine open-market purchase — a 10%+ owner accumulating in a nutritional supplement company against a pullback from the $16–17 range toward $15.77. The multi-day, multi-tranche pattern (Aug 6–10) is characteristic of a deliberate accumulation strategy rather than a single conviction buy. Prescott Group has held a large position since at least mid-2025.
Overall insider purchase activity on August 10–11 was sparse — heavy on sales and option exercises, with no officer-level open-market buys at major-cap names. Excluding the IPO-linked purchases, meaningful organic conviction buys were limited to NATR.
Most-bought stocks, last 30 days
SCTX$56.3M · 3 buys, 3 insidersScribe Therapeutics Inc.
COE$56.2M · 7 buys, 2 insiders51Talk Online Education Group
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's
stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what
average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free,
and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.